TABLE 3

Neurodevelopmental Outcomes at 16–36 mo Follow-Up According to HC Growth During Various Time Periods

OutcomeTime PeriodΔHC z Score
<−2 Group 2 aOR (95% CI)−2 to −1.01 Group 3 aOR (95% CI)+1.01 to +2 Group 4 aOR (95% CI)>+2 Group 5 aOR (95% CI)
sNDIAdmission to discharge1.38 (1.01 to 1.89)1.1 (0.79 to 1.53)0.6 (0.27 to 1.37)0.94 (0.42 to 2.07)
Discharge to follow-up2.14 (0.99 to 4.63)0.81 (0.38 to 1.72)0.82 (0.59 to 1.14)1.03 (0.75 to 1.41)
Admission to follow-up2.18 (1.5 to 3.15)1.31 (0.87 to 1.99)0.98 (0.66 to 1.45)1.09 (0.66 to 1.78)
NDIAdmission to discharge0.98 (0.78 to 1.24)0.96 (0.76 to 1.21)0.56 (0.33 to 0.93)1.43 (0.82 to 2.5)
Discharge to follow-up1.82 (0.89 to 3.72)0.71 (0.41 to 1.23)0.93 (0.74 to 1.17)1 (0.79 to 1.26)
Admission to follow-up1.23 (0.9 to 1.68)1.34 (0.99 to 1.81)1.11 (0.86 to 1.44)1.03 (0.73 to 1.45)
  • Group 1 is the reference group and all results are in relation to Group 1. The results are adjusted for GA, sex, SGA, antenatal steroid use, SNAPII score and Caesarian section.